Cargando…

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas

SIMPLE SUMMARY: Since the publication in 2016 of the WHO’s classification of primary brain tumors according to their histopathology but also their molecular status (IDH, 1p/19q codeletion), oligodendrogliomas defined by the presence of the 1p/19q codeletion have been clearly identified as having a b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilhodes, Julia, Meola, Adèle, Cabarrou, Bastien, Peyraga, Guillaume, Dehais, Caroline, Figarella-Branger, Dominique, Ducray, François, Maurage, Claude-Alain, Loussouarn, Delphine, Uro-Coste, Emmanuelle, Cohen-Jonathan Moyal, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296584/ https://www.ncbi.nlm.nih.gov/pubmed/37370678 http://dx.doi.org/10.3390/cancers15123067

Ejemplares similares

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome
por: Appay, Romain, et al.
Publicado: (2018)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study
por: Garnier, Louis, et al.
Publicado: (2022)

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
por: Ducray, François, et al.
Publicado: (2008)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

TCF12 is mutated in anaplastic oligodendroglioma
por: Labreche, Karim, et al.
Publicado: (2015)

SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas
por: Idbaih, Ahmed, et al.
Publicado: (2012)

Correction: SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas
por: Idbaih, Ahmed, et al.
Publicado: (2013)

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
por: Lee, Julieann, et al.
Publicado: (2018)

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas
por: Grandin, Nathalie, et al.
Publicado: (2019)

Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review
por: Shimizu, Hiroyuki, et al.
Publicado: (2020)

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
por: Habiba, Umma, et al.
Publicado: (2021)

Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma
por: Ma, Sirui, et al.
Publicado: (2021)

Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas
por: Kamoun, Aurélie, et al.
Publicado: (2016)

The Implementation of DNA Methylation Profiling into a Multistep Diagnostic Process in Pediatric Neuropathology: A 2-Year Real-World Experience by the French Neuropathology Network
por: Pages, Melanie, et al.
Publicado: (2021)

Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
por: Zreik, Jad, et al.
Publicado: (2021)

Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort
por: Allwohn, Luisa, et al.
Publicado: (2023)

CeRNA Network Analysis Representing Characteristics of Different Tumor Environments Based on 1p/19q Codeletion in Oligodendrogliomas
por: Ahn, Ju Won, et al.
Publicado: (2020)

Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults
por: Picart, Thiébaud, et al.
Publicado: (2021)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study
por: Montégut, Coline, et al.
Publicado: (2022)

Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review
por: Brandner, Sebastian, et al.
Publicado: (2022)

Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients
por: Al Saati, Ayman, et al.
Publicado: (2023)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Characteristics of gliomas in patients with somatic IDH mosaicism
por: Bonnet, Charlotte, et al.
Publicado: (2016)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report
por: Agopyan-Miu, Alexander H. C. W., et al.
Publicado: (2021)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

CNS neuroblastoma, FOXR2-activated and its mimics: a relevant panel approach for work-up and accurate diagnosis of this rare neoplasm
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2023)

Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results
por: Pouessel, Damien, et al.
Publicado: (2023)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status
por: Pesenti, Chiara, et al.
Publicado: (2017)

Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion
por: Métais, Alice, et al.
Publicado: (2023)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

T(2)-FLAIR Mismatch Sign Is Caused by Long T(1) and T(2) of IDH-mutant, 1p19q Non-codeleted Astrocytoma
por: Kinoshita, Manabu, et al.
Publicado: (2020)

The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations
por: Siakallis, Loizos, et al.
Publicado: (2023)

Translation reprogramming by eIF3 linked to glioblastoma resistance
por: Bertorello, Juliette, et al.
Publicado: (2020)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hi6th5qgu021s13tqdeo324cd6